NCT06717464View on ClinicalTrials.gov

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Gallbladder CancerHilar CholangiocarcinomaDistal Cholangiocarcinoma
Interventions
DRUG

Capecitabine

1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)

DRUG

Toripalimab

240mg intravenous injection, q3w, for 54 weeks (18 cycles)

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER